5 citations
,
December 1981 in “PubMed” Metoprolol, a blood pressure medication, was linked to reversible hair loss.
34 citations
,
February 1992 in “Naunyn-schmiedebergs Archives of Pharmacology” Tedisamil and glibenclamide affect cromakalim and minoxidil sulphate differently in rat aorta.
19 citations
,
May 1979 in “Archives of internal medicine” Minoxidil effectively lowers blood pressure and initially increases plasma renin activity without raising aldosterone levels.
June 1982 in “Reactions (Auckland)” Metoprolol and propranolol may cause hair loss.
142 citations
,
March 2019 in “Frontiers in Cellular Neuroscience” The document concludes that adenosine receptor agonists have potential for treating various conditions, but only a few are approved due to challenges like side effects and the need for selective activation.
25 citations
,
December 1974 in “Clinical Pharmacology & Therapeutics” Propranolol affects heart rate and renin levels in minoxidil-treated patients.
January 2026 in “American Journal of Translational Research” The metoprolol-spironolactone combination improves heart function in patients with coronary heart disease and heart failure.
14 citations
,
April 2009 in “Acta Medica Scandinavica” Minoxidil helps control blood pressure but has side-effects, so it's not for everyone.
1 citations
,
March 2023 in “Journal of the American College of Cardiology” 6 citations
,
February 2025 in “International Journal of Molecular Sciences” The new system greatly improves carvedilol's solubility and effectiveness.
6 citations
,
January 2021 in “Journal of The American Academy of Dermatology” Low-dose oral minoxidil can be effective for hair loss but should be avoided in people with certain heart conditions and severe liver problems.
17 citations
,
May 1975 in “Clinical Pharmacology & Therapeutics”
September 2022 in “JAAD Case Reports” A man got heart and swelling issues from a hair loss medication, so doctors advise careful use, especially in people with past health problems.
June 2023 in “Frontiers in Cardiovascular Medicine” Using existing drugs for new purposes could be a cost-effective way to treat chest pain and non-clogged heart arteries, with some drugs for lung blood pressure showing promise but needing more testing.
40 citations
,
July 2011 in “The journal of clinical hypertension” Hydralazine and minoxidil are blood pressure medications that relax blood vessels, with potential side effects like rapid heartbeat and fluid retention, and are used for severe or pregnancy-related hypertension.
55 citations
,
October 1975 in “Circulation” Minoxidil, propranolol, and furosemide effectively control severe hypertension, but may cause sodium retention.
1 citations
,
September 2023 in “Dermatology online journal” Low dose oral minoxidil can help with hair growth but may cause serious heart problems, so doctors need to be careful.
14 citations
,
October 1977 in “The Lancet”
55 citations
,
March 1973 in “PubMed” Minoxidil is a new drug that lowers blood pressure.
Minoxidil can cause hair growth as a side effect.
July 2024 in “Journal of Investigative Dermatology” Low-dose oral minoxidil is safe for alopecia patients, even those prone to edema.
3 citations
,
February 1985 in “PubMed” Stopping the beta-blocker nadolol led to quick hair regrowth and improved scalp condition.
July 2025 in “Journal of Investigative Dermatology” Low-dose oral minoxidil is safe for the heart in the short term for hair loss patients.
90 citations
,
January 1989 in “PubMed” May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly”
March 2025 in “Journal of the American Academy of Dermatology” Low-dose oral minoxidil doesn't affect blood pressure in patients taking blood pressure meds.
September 2024 in “Journal of Cosmetic Dermatology” Low-dose oral minoxidil can cause serious side effects like heart issues, so use the lowest effective dose.
25 citations
,
December 2001 in “Expert Opinion on Pharmacotherapy” Potassium channel openers show promise for treating heart disease and other conditions, but more research is needed to fully understand their effects and safety.
March 2024 in “Journal of the American Academy of Dermatology”